Pharmaceutical composition (A) comprises an agent (I) that inhibits the expression or activity of a tumor-associated antigen (TAg) that is encoded by a nucleic acid (NA) that: (a) is any of 22 specified sequences (reproduced) or their fragments or derivatives (b) hybridizes to (a) under stringent conditions (c) is a degenerate variant of (a) or (b) or (d) is the complement of (a)-(c). Independent claims are also included for: (1) pharmaceutical composition (A1) comprising an agent (Ia) with tumor-inhibiting activity that is selective for cells showing (abnormal) expression of TAg (2) pharmaceutical composition (A2) comprising an agent (Ib) that selectively increases the amount of complex formed between an HLA molecule and TAg, or its fragments (3) pharmaceutical composition (A3) containing one or more of TAg (or its fragments), NA that encodes TAg, antibodies (Ab) that bind TAg, antisense nucleic acids that hybridize specifically to NA, and host cells that express TAg (4) diagnosing a disease associated with (abnormal) expression of TAg (5) determining regression, progression or onset of a disease associated with (abnormal) expression of TAg (6) treating a disease associated with (abnormal) expression of TAg (7) treatment, diagnosis or monitoring of a disease associated with (abnormal) e xpression of TAg (8) inhibiting development of cancer by administering any of A1-A3 (9) new nucleic acid (NA1) that is any of 3 specified sequences (reproduced included within NA), their fragments or derivatives, degenerate variants, complements or sequences that hybridize to them (10) nucleic acid (NA2) that encodes a protein/polypeptide having any of 4 amino acid (aa) sequences reproduced, or their fragments or derivatives (11) recombinant DNA or RNA (NA3) that comprises NA1 or NA2 (12) host cells that contain NA1-NA3 (13) protein or polypeptide (P) encoded by NA1 or containing the aa sequences of (10) (14) immunogenic fragments of (P) and fragments that can bind to human HLA rece
